ClinicalTrials.gg
CompletedNCT01143077SWITCHCoreUpdated Apr 17, 2013Results posted

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

A Phase 3 interventional study of Lurasidone HCl in Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
14th of 39
244 · median 149
Started
2010
with 1 other
Phase 3
18 of 39
none open now
Registered
15th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 14th largest by enrollment, is one of 2 that started in 2010, is one of 18 in phase 3, and was the 15th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Lurasidone
  • Schizophrenia
  • Latuda
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject ≥ 18 years of age.
  • Subject meets criteria for a primary diagnosis of schizophrenia or schizoaffective disorder.
  • Subject must be judged by the investigator to be an appropriate candidate for switching current antipsychotic medication due to insufficient efficacy and/or safety or tolerability concerns.

Exclusion criteria

Exclusion Criteria:

  • Presence of an Axis I or Axis II disorder other than schizophrenia or schizoaffective disorder that is the primary focus of treatment prior to screening.
  • Subject has experienced persistent lack of improvement in psychotic symptoms despite adequate trials (at least 6 weeks at standard doses), of two or more antipsychotic agents in the 12 months prior to screening.
  • Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or property. Subject has suicidal ideation at baseline or has attempted suicide within 90 days prior to randomization (even without hospitalization).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Lurasidone Open-Label Arm A

    Drug: Lurasidone HCl

  • Experimental
    Lurasidone Open-Label Arm B

    Drug: Lurasidone HCl

  • Experimental
    Lurasidone Open-Label Arm C

    Drug: Lurasidone HCl

Interventions

  • Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks

    Also known as: Latuda

06

What researchers measure

Primary outcomes

  1. Time to Relapse of Psychotic Symptoms During 6 Weeks

    Relapse is defined as any occurrence of: * Insufficient clinical response * Exacerbation of underlying disease * Discontinuation due to an adverse event

    Time frame: 6 Weeks

Secondary outcomes

  1. Tolerability and Safety

    Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

    Time frame: 6 Weeks

07

Results

Posted Aug 16, 2012

Participant flow

FPI June 24, 2010-LPV May 19, 2011, locations were private health clinics, university hospitals, private research facilities.

Participant flow — Overall Study
MilestoneLurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80
Started748882
Completed587367
Not completed161515
Withdrew: Lack of efficacy021
Withdrew: Adverse event565
Withdrew: Lost to follow-up234
Withdrew: Protocol violation200
Withdrew: Withdrawal by subject433
Withdrew: Non-compliance with study drug011
Withdrew: Administrative100
Withdrew: Principal investigator decision201

Outcome measures

PrimaryTime to Relapse of Psychotic Symptoms During 6 Weeks

Relapse is defined as any occurrence of: * Insufficient clinical response * Exacerbation of underlying disease * Discontinuation due to an adverse event

Time frame:
6 Weeks
Reported as:
Mean · days
Time to Relapse of Psychotic Symptoms During 6 Weeks
daysLurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80
Time to Relapse of Psychotic Symptoms During 6 Weeks23.8 ± 12.116.9 ± 11.617.3 ± 8.9
SecondaryTolerability and Safety

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

Time frame:
6 Weeks
Reported as:
Number · participants
Tolerability and Safety
participantsLurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80
Tolerability and Safety728781

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone Open-Label Arm 40/40—3/72 (4.2%)45/72 (62.5%)
Lurasidone Open-Label Arm 40/80—2/87 (2.3%)62/87 (71.3%)
Lurasidone Open-Label Arm 80/80—0/81 (0%)59/81 (72.8%)
Most frequent serious events
Most frequent serious events
EventLurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80
Schizoaffective disorderPsychiatric disorders2/720/870/81
OsteoarthritisMusculoskeletal and connective tissue disorders1/720/870/81
SchizophreniaPsychiatric disorders1/720/870/81
AlcoholismPsychiatric disorders0/721/870/81
Sexually inappropriate behaviorPsychiatric disorders0/721/870/81
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80
NauseaGastrointestinal disorders10/728/8715/81
InsomniaPsychiatric disorders3/7216/8712/81
AkathisiaNervous system disorders6/7213/8711/81
HeadacheNervous system disorders7/7210/876/81
Dry MouthGastrointestinal disorders3/729/872/81
SomnolenceNervous system disorders7/727/872/81
VomitingGastrointestinal disorders4/726/877/81
AnxietyPsychiatric disorders2/726/871/81
SedationNervous system disorders3/722/875/81
FatigueGeneral disorders3/725/872/81

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80Total
<=18 years1102
Between 18 and 65 years718581237
>=65 years0101
Age Continuous
Age Continuous(years)Lurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80Total
Mean43.2 ± 11.344.0 ± 11.544.4 ± 10.043.9 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80Total
Female25372284
Male475059156
Region of Enrollment
Region of Enrollment(participants)Lurasidone Open-Label Arm 40/40Lurasidone Open-Label Arm 40/80Lurasidone Open-Label Arm 80/80Total
United States728781240
08

Study locations

27 sites
  • K and S Professional Research Services
    Little Rock, Arkansas 72201, United States
  • Synergy Clinical Research of Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • Pacific Research Partners, LLC
    Oakland, California 94612, United States
  • California Clinical Trials
    Paramount, California 90723, United States
  • Pasadena Research Institute
    Pasadena, California 91107, United States
  • California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC
    Pico Rivera, California 90660, United States
  • California Neuropsychopharmacology Clinical Research Institute (CNRI)
    San Diego, California 92102, United States
  • University of California San Diego Medical Center
    San Diego, California 92103-8218, United States
  • Collaborative Neuroscience Network, South Bay
    Torrance, California 90502, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80204, United States
  • Comprehensive NeuroScience, Inc.
    Atlanta, Georgia 30328, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70601, United States
  • Saint Charles Psychiatric Associates/Midwest Research Group
    St. Charles, Missouri 63301, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • The Zucker Hillside Hospital
    Glen Oaks, New York 11004, United States
  • Duke University Dept. of Psychiatry
    Durham, North Carolina 27710, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • CRI Worldwide - Kirkbride Center
    Philadelphia, Pennsylvania 19131, United States
  • FutureSearch Clinical Trials, LP
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-8828, United States
  • Wharton Research Center
    Houston, Texas 77488, United States
  • University of Utah Hospitals and Clinics
    Salt Lake City, Utah 84132, United States
09

References and documents

Publications

  • McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013 Feb;74(2):170-9. doi: 10.4088/JCP.12m07992. PubMed 23473350 ↗
  • Awad G, Hassan M, Loebel A, Hsu J, Pikalov A, Rajagopalan K. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC Psychiatry. 2014 Feb 23;14:53. doi: 10.1186/1471-244X-14-53. PubMed 24559217 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2010
First posted
Jun 14, 2010
Start
Jun 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Aug 16, 2012
Last update
Apr 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01143077
Responsible party
Sponsor
First posted
Jun 14, 2010
Start date
Jun 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Aug 16, 2012
Last update
Apr 17, 2013

Study contacts

Lurasidone Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion